There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available;dialysis and transplantation are performed at costs of >$2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKD patients.

Public Health Relevance

There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available;dialysis and transplantation are performed at costs of >$2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKD patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43DK098959-01A1
Application #
8646478
Study Section
Special Emphasis Panel (ZRG1-DKUS-N (11))
Program Officer
Moxey-Mims, Marva M
Project Start
2013-09-16
Project End
2014-06-30
Budget Start
2013-09-16
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$415,078
Indirect Cost
Name
Novatarg, Inc.
Department
Type
DUNS #
962942863
City
Durham
State
NC
Country
United States
Zip Code
27708